At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our exome and genome tests translate complex genomic data into clinical answers. It all starts with a single test. for more information, please visit https://www.genedx.com

Vicero is a preclinical biopharmaceutical company pioneering the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology. The VINCOBODY product engine is proprietary VHH modular technology that enables Vicero to build best in class IO and ADC therapeutics with the potential to address unmet need in the immuno-oncology solid tumor market. Our team of experienced scientists and drug developers has delivered more than 20 life extending therapies to patients in need. For more information, please visit us at www.vicerobio.com or our LinkedIn page

Since 2008, we at i-Pharm have specialized in life sciences recruitment, supporting Pharmaceutical, Biotech, MedTech and CRO companies globally. With offices in major hubs, we deliver high-quality recruitment solutions, focusing on Medical Affairs, Clinical Development, Clinical Operations, Regulatory Strategy, CMC, and Commercial sectors, driven by strong values and industry expertise. For more information, please visit https://www.i-pharmconsulting.com/

Delivering the power of T cells to cancer patients. For more information, visit https://immatics.com/

Our network of treating physicians refer their protocol eligible, highly motivated patients directly to your sites.  Our model is entirely pay for performance.

Coherus is a commercial-stage innovative oncology company with a US FDA approved PD-1 inhibitor, LOQTORZI, as well as two proprietary pipeline products; a first in class Phase 2 anti-IL-27, casdozokitug, being developed in combination with LOQTORZI for the treatment of liver and lung cancer and a highly selective cytolytic CCR8 antibody, CHS-114, being developed in combination with LOQTORZI in head and neck squamous cell carcinoma and gastric cancer. Clinical data readouts are occurring in 2025 supporting these studies with safety, initial efficacy and proof of mechanism that builds momentum with initial key data readouts for these studies being projected to occur in H1 2026.LOQTORZI is the only FDA-approved treatment for metastatic/recurrent locally advanced nasopharyngeal carcinoma in all lines of therapy and the new standard of care. LOQTORZI was launched in the U.S. in Q1 2024 and is expected to reach $150M to $200M in sales within three to four years.In addition, LOQTORZI is being evaluated in two pivotal clinical trials, which could expand the label into additional indications in the U.S.. The first is in combination with anti-BTLA, tifcemalimab, in small cell lung cancer sponsored by Junshi BioSciences and the second is planned to open in the 2H of 2025 in combination with INO-3112 in locally advanced high-risk HPV positive head and neck cancer.Coherus is focused on expanding the indications for LOQTORZI in combination with other agents to extend patient survival across tumor types. The market opportunity addressed by current pipeline candidates is up to $15B annually. For more information please visit https://www.coherus.com/.

Rivia is an integrated trial monitoring platform with AI-driven analytics, designed for clinical teams and medical leadership. It unifies data across vendors in days, enabling earlier interpretation and effective action on trial data. Sponsors like Alentis and Altrubio monitor patients and generate reports in minutes, unlocking the full potential of their therapies. For more information, please visit rivia.com

Yonalink is a leader in EHR-to-EDC data streaming, transforming how clinical trial data is collected and shared. Our platform seamlessly transfers data from hospital electronic health records to electronic data capture systems, accelerating trial timelines, improving data accuracy, and reducing site burden. Yonalink drives innovation and efficiency in global clinical research. For more information, please visit yonalink.com

TPS delivers customized, cost-effective solutions designed to accelerate study success. Our models drive faster study start-up, streamline site enablement, optimize patient enrollment, enhance site management, improve monitoring efficiency, and strengthen data integrity. By deploying dedicated, therapeutically aligned professionals, we ensure every aspect of your study is optimized for quality and performance. For more information, please visit https://www.tpsglobal.com/

Synaptimmune and its partners are leveraging its best in class long acting conditionally active Costimulatory T cell engager platform (TROY-Ig) for targeting Autoimmune diseases and Cancers.

Evernorth Health Services unites businesses such as Express Scripts® and Accredo Specialty Pharmacy® to unlock opportunities and value with advanced analytics, predictive models, and tailored insights. Connect with our team to learn how our innovative clinical trial solutions tap into connected pharmacy and medical data to help you identify, understand and mitigate risk. For more information, please visit https://www.evernorth.com/our-solutions/clinical-trial-research 

Myonex integrates clinical trial supply and commercial pharmaceutical services to reduce time, costs, and complexity. Our global presence and expert project management ensure seamless, flexible, and high-quality execution. For more information, visit https://www.myonex.com/